Long time comin': Chelsea wins FDA OK for Northera in NOH, finally
This article was originally published in Scrip
After two advisory panel meetings, years of back-and-forths with the FDA and a lot of investor rollercoaster rides, Chelsea Therapeutics' Northera (droxidopa) finally won US approval on 18 February as a therapy for patients with symptomatic neurogenic orthostatic hypotension (NOH), a chronic disorder caused by a deficient release of norepinephrine, which results in a sudden drop in blood pressure when a person goes from a supine position to standing.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.